The initial presenting features of early rheumatoid arthritis do not substantially differ from other forms of inflammatory arthritis.1
Patients can present with a wide range of manifestations, including a history of swelling in joints, early morning stiffness lasting greater than 30 minutes, and systemic symptoms such as tiredness combined with objective evidence of synovitis (inflammation of the membrane lining joints).2There are a wide range of conditions that can mimic rheumatoid arthritis:2
Hepatitis B or C
Inflammatory bowel disease
Connective tissue diseases
Systemic lupus erythematosus
Sarcoidosis, thyroid disease
Laboratory investigations should be used to help identify rheumatoid arthritis early, potentially leading to improved patient outcomes1
Rheumatoid arthritis has a global prevalence of 0.24%3
Early detection and appropriate treatment of rheumatoid arthritis can affect the disease course, prevent the development of joint erosion, and/or retard progression of erosive disease1
Up to 20% of rheumatoid arthritis patients have rheumatoid factor but do not have anti-CCP antibodies4
What are the benefits of early diagnosis?
Early identification and treatment of rheumatoid arthritis can:1
Affect the disease course
Prevent the development of joint erosion
Retard progression of erosive disease
In fact, rheumatoid arthritis may be considered a potentially curable condition if identified and treated during the evolutionary process from inflammatory arthritis to established disease.1
How can tests be used to personalise care?
Out of a large number of inflammatory markers, including erythrocyte sedimentation rate and C-reactive protein, there are only a few tests that are specific for rheumatoid arthritis. When used together, these tests can provide considerable diagnostic and prognostic guidance in the early diagnosis of rheumatoid arthritis patients.1
Anti-CCP antibodies are detectable several years before the onset of rheumatoid arthritis, and patients with anti-CCP antibodies are more likely to have severe disease5,6
Rheumatoid factor IgM
Up to 20% of rheumatoid arthritis patients have rheumatoid factor but do not have anti-CCP antibodies.4 These patients can be identified by testing for rheumatoid factor IgM. In non-symptomatic subjects, rheumatoid factor IgM is a risk factor for developing rheumatoid arthritis; risk is related to the titre7
Rheumatoid factor IgA
Elevated rheumatoid factor IgA correlates with disease activity, and indicates a poor clinical response to TNF-α inhibitors. Therefore, testing for rheumatoid factor IgA provides additional prognostic guidance7-9
Rheumatoid factor IgG
In non-symptomatic subjects, rheumatoid factor IgG is a risk factor for developing rheumatoid arthritis; risk is related to the titre7
Together, these tests can help to identify rheumatoid arthritis patients sooner; identify patients that are at risk of more severe disease; identify patients who are less likely to respond to TNF-α inhibitors; and enable clinicians to start tailored treatment sooner.1,5-9 Like all tests, these tests should always be interpreted in conjunction with a clinical history
This educational website, provided by Thermo Fisher Scientific, ImmunoDiagnostics Division, has been produced in partnership with the Institute of Biomedical Science as a pioneering venture to promote excellence in laboratory practice using education and continuing professional development (CPD) resources.
The information contained within this website is intended for laboratory professionals.
By entering this website you are confirming that you are a laboratory professional.
Are you interested in receiving information from Thermo Fisher Scientific?